Pharmaceuticals News and Research

RSS

Cytrx announces Q3 2013 financial results, provides clinical update

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and nine-month periods ended September 30, 2013, and provided a clinical update.

29 Oct 2013

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Biogen Idec Inc. today reported third quarter 2013 total revenues of $1.8 billion, an increase of 32% over the third quarter of 2012. Non-GAAP diluted EPS for the third quarter of 2013 were $2.35, an increase of 23% over the third quarter of 2012.

28 Oct 2013

Potential, low-cost approach to improve exercise adherence in knee osteoarthritis patients

New research presented at the American College of Rheumatology Annual Meeting in San Diego describes an exciting novel tool utilizing telephone linked technology that shows potential as a low cost approach to improving exercise adherence in patients with knee osteoarthritis.

28 Oct 2013

Researchers discover novel genetic cause of severe obesity

Researchers from the University of Cambridge have discovered a novel genetic cause of severe obesity which, although relatively rare, demonstrates for the first time that genes can reduce basal metabolic rate - how the body burns calories.

25 Oct 2013

DSM, Sanquin Make Factor IX-Recovering Mab Manufacturing Deal

...

24 Oct 2013

McKesson’s revenues increase 11% to $33B in second quarter 2014

McKesson Corporation (NYSE:MCK) today reported that revenues for the second quarter ended September 30, 2013 were $33 billion, up 11% compared to $29.8 billion a year ago. On the basis of U.S. generally accepted accounting principles ("GAAP"), second-quarter earnings per diluted share was $1.74 compared to $1.67 a year ago.

24 Oct 2013

ICON Q3 net revenues increase 19% to $339.8 million

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the third quarter ended September 30, 2013.

24 Oct 2013

Alexion Pharma's replacement therapy gets FDA Breakthrough Therapy designation for MoCD Type A

Alexion Pharma International Sàrl, a subsidiary of Alexion Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has granted a Breakthrough Therapy designation to cyclic pyranopterin monophosphate (cPMP, or ALXN1101), an enzyme co-factor replacement therapy for the treatment of patients with molybdenum cofactor deficiency type A, a severe and life-threatening, ultra-rare, genetic metabolic disorder that causes catastrophic and irreversible neurologic damage within the first weeks of life.

24 Oct 2013

New Centre for Stratified Medicine opened in Ireland

The University of Ulster has opened a new Centre for Stratified Medicine. The only Centre of its kind in Ireland, £11.5m research facility in Derry~Londonderry puts the University at the forefront of medical research into chronic degenerative diseases.

24 Oct 2013

McKesson agrees to acquire majority stake in Celesio

McKesson Corporation, a leading North American healthcare services and information technology company, and Celesio AG, a leading international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors, announced today that McKesson has signed an agreement to acquire a majority stake in Celesio for €23 per share and to launch parallel voluntary public tender offers for the remaining publicly-traded shares and outstanding convertible bonds of Celesio.

24 Oct 2013

Unique approach to help discover how cell changes shape in response to topographies

Cells in the human body change shape as they crawl, split, or cling to other surfaces, but while the scientific literature is filled with examples of how cell shapes shift in response to things they touch, little is known about the rules that govern these changes. And there has been no high-throughput way to systematically test different topologies against different types of cells to optimize the surface of something like a medical implant.

24 Oct 2013

Researchers describe why current medications only moderately reduce Fragile X symptoms

When you experience something, neurons in the brain send chemical signals called neurotransmitters across synapses to receptors on other neurons. How well that process unfolds determines how you comprehend the experience and what behaviors might follow. In people with Fragile X syndrome, a third of whom are eventually diagnosed with Autism Spectrum Disorder, that process is severely hindered, leading to intellectual impairments and abnormal behaviors.

24 Oct 2013

APPG-GTB members express concern on the growing threat of multi-drug resistant TB

In a Lancet Comment discussing the WHO Global Tuberculosis report 2013 published today [Wednesday 23 October], members of the UK All-Party Parliamentary Group on Global Tuberculosis and lead author Professor Ali Zumla from University College London sound an alarm as the growing threat of multi-drug resistant TB to regional and global health security becomes more apparent.

23 Oct 2013

Promising technique for treating eye disease proves effective in preclinical studies

A promising technique for treating human eye disease has proven effective in preclinical studies and may lead to new treatments to prevent blindness, according to experiments conducted at The Scripps Research Institute in La Jolla, California.

23 Oct 2013

Scientists from University of Salzburg, Sandoz Pharmaceuticals and Thermo Fisher Scientific collaborate to advance protein-based pharmaceutical development

The Christian Doppler Laboratory for Biosimilar Characterization is now open at the Paris-Lodron University of Salzburg, and scientists there have commenced developing new methods for characterizing proteins to be used in biopharmaceuticals.

23 Oct 2013

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013